Immunodiagnostic Reagent offers 2-year stability.
Press Release Summary:
Maintaining stability for 2 years at 25°C or 4 years at 4°C, BioFX® TMB Enhanced HRP Membrane Substrate is suited for diagnostic kits and point-of-care applications. One-component formulation is ready to use with no mixing. Product minimizes membrane wash out at high peroxidase concentrations, allowing for measurement of extended dynamic range. Sensitivity is similar to most mid- to high-level chemiluminescent membrane substrates.
Original Press Release:
SurModics IVD Introduces a New BioFX® TMB Enhanced HRP Membrane Substrate A Winner of the LifeScience Alley® 2011 New Technology Showcase!
EDEN PRAIRIE, Minn. -- SurModics IVD introduces BioFX® TMB Enhanced HRP Membrane Substrate. SurModics IVD, a wholly owned subsidiary of SurModics, Inc. (Nasdaq: SRDX), is a market leader for immunoassay reagents for diagnostic test kits used to detect absence or presence of disease.
BioFX TMB Enhanced HRP Membrane Substrate (ESPM) is the latest addition to SurModics IVD's family of quality, market-proven immunodiagnostic reagents. BioFX TMB ESPM's one-component formulation was developed to provide room temperature stability for two years, a unique feature making it an ideal choice for diagnostics kits and point-of-care (POC) applications. BioFX TMB ESPM reduces membrane wash out at higher peroxidase concentrations, allowing for measurement of an extended dynamic range.
Features of BioFX TMB Enhanced HRP Membrane Substrate include:
o One-component formulation - ready to use with no mixing
o Similar sensitivity to most mid- to high-level chemiluminescent membrane substrates without the costly equipment needed for detection
o Stable formulation
- Two years at 25°C
- Four years at 4°C
o Extended dynamic range with reduction of wash out at higher peroxidase concentrations
This product was recently selected for presentation in the New Technology Showcase at the LifeScience Alley® Conference & Expo 2011 to be held in Minneapolis, MN on December 7, 2011. "We are very excited that BioFX TMB ESPM was chosen as a winner for the 2011 New Technology Showcase presentation and believe its unique features will provide solutions for the challenges faced by the diagnostics industry for POC and membrane applications." said Gary Maharaj, CEO and president of SurModics. "SurModics remains committed to developing additional products for the in vitro diagnostic market, enabling us to better serve our customers' needs."
To learn more about SurModics' in vitro diagnostic products, please visit our website (www.surmodicsivd.com), or contact customer service at 952-500-7200 or orders@surmodics.com.
About SurModics, Inc.
SurModics' vision is to extend and improve the lives of patients through technology innovation. The Company partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics, along with its subsidiary SurModics IVD, Inc., is headquartered in Eden Prairie, Minnesota and its SurModics Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit www.surmodics.com. The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.
